MTOR and hepatocellular carcinoma: Regarding the management of patients undergoing LT for HCC, the authors recommended steroid-free immunosuppression and the reduction in CNI exposure by introducing mTOR inhibitors, given their anti-tumor potential [84,85,86,90].